8:00am – 8:55am

Breakfast
Sponsored by Syngene International

8:55am – 9:00am

Opening Remarks

9:00am – 9:05am

Introducing Mark Altmeyer:
Wendy Goldstein
Member of the Firm
Epstein Becker & Green PC

9:05am – 9:35am

"Innovation and Efficiency: A Virtual Solution"

Mark Altmeyer
President and Chief Executive Officer
Otsuka America Pharmaceutical, Inc.

9:40am – 10:30am

Panel Discussion

"The Environment for New Drug Development"

Session topics include but are not limited to:

• How can we get new and innovative drugs into the large pharmaceutical companies?
• Pipeline issues.
• Discovery process v. strategic alliances- the pros and cons of both methods of new drug integration.

Moderator:
Dimitri Drone
Transaction Services Pharmaceutical and Life Sciences Leader
PricewaterhouseCoopers

Panelists:
David H. Donabedian, PhD, MBA
Vice President, Strategic Alliances
US CEEDD, GSK

Simeon J. George, M.D.
Partner
SR One

Julius Knowles
Head, Platforms, Strategic Alliances
Novartis Institutes for BioMedical Research

Michael Mentesana
US Pharmaceutical and Life Sciences R&D Advisory Services Leader
PricewaterhouseCoopers

Richard C. Pasternak, M.D.
VP, Head Global Scientific Affairs and Scientific Leadership
Merck

10:30am – 10:55am

Coffee Break

10:55am – 11:45am

Panel Discussion

"A Discussion on the Role of Generics"

Session topics include but are not limited to:

• What is the future of generic and branded generic drug competition and biosimiliars?
• How can Pharma/biotech deal with impending generic competition?
• How can Emerging Markets be an outlet for new profit? What are the promises and challenges?
• Drug portfolio diversification?  How do you avoid putting "all of our eggs in one basket" but remain focused?
• Implications for deal flow.

Moderator:
Dr. Robert J. Spiegel, M.D. 
Former Chief Medical Officer and Senior Vice President, Schering-Plough Corporation
and
Founder, Spiegel Consulting LLC

Panelists:
Mike Chace-Ortiz
Senior Director of Product Strategy
Thomson Reuters

Veronica Mullally
Partner
Hogan Lovells

Garry Neil, MD
Corporate Vice President, Corporate Office of Science & Technology
Johnson & Johnson

Hans Vemer
Former Senior Vice President- Women’s Health
Schering-Plough

11:50am – 12:20pm

"Bristol-Myers Squibb's Evolution from a Big Pharma Company to a Mid Size Biopharma Company"

Mark Powell
Senior Vice President, Pharmaceutical Development
Bristol-Myers Squibb

Session topics include but are not limited to:

• BMS has strategically differentiated themselves from their Big Pharma peer group
• They have transformed into a more productive, focused and simplified company
• BMS utilizes a selectively integrated business model with the degree of integration determined by asset
• Several preclinical examples are highlighted of their Biopharma culture and execution
• Early industry data suggests the strategy is working in terms of overall productivity

12:20pm – 1:25pm

Lunch

1:25pm – 2:15pm

Panel Discussion

"Deal Making in the Pharmaceutical and Biotech Industries"

Session topics include, but are not limited to:

• How will economic recovery play a role in pharmaceutical M&A? As the recession begins to subside, will we continue to see an uptick in deals?
• Predictions on where deals will be found going forward.
• What deal structure is going to work given the changing regulatory landscape?

Moderator:
Paunie Samreth
Reporter
mergermarket

Panelists:
Chris Garabedian
Vice President, Corporate Strategy
Celgene Corporation

Adam Golden
Partner and Co-Chair, Life Sciences Group 
Kaye Scholer LLP

Reid J. Leonard, Ph.D.
Executive Director, Licensing & External Research
Merck Research Laboratories

Elizabeth Stoner, M.D., M.S.
Managing Director
MPM Capital

Mike Wise
Vice President and Partner
A.T. Kearney

*This session is off the record

2:15pm – 2:30pm

Thought Leadership Spotlight
Presented by Nutter McClennan & Fish LLP

"Government Investigation: Triggers and Responses"

Robert L. Ullmann
Chair, Government Investigations and White Collar Defense
Nutter McClennan & Fish LLP

Session topics include, but are not limited to:

• Reflections on the patterns of business conduct that often lead to government investigations, and the most effective ways to respond to such investigations, externally and internally.

2:30pm – 2:35pm

Introducing Rod MacKenzie:
Jessica Kirk
Vice President - Life Sciences
Gerson Lehrman Group

2:35pm – 3:05pm

"R&D Networks: Lighting Up the Grid:

Radically optimistic thoughts on Research in Pharma R&D"

Rod MacKenzie
Senior Vice President, Head of PharmaTherapeutics R&D
Pfizer Inc

3:05pm – 3:35pm

Coffee Break

3:35pm – 4:05pm

“The Return of the Truffle Hunter”

Stephen Evans-Freke
Co-Founder and Managing General Partner
Celtic Therapeutics

Session topics include, but are not limited to:

• The failure of big pharma’s efforts to scale up drug discovery and early-stage development, and the need for new industry models.

4:05pm – 4:10pm

Introducing Elaine V. Jones, Ph.D.:
David Fox
Partner
Hogan Lovells US LLP

4:10pm – 4:40pm

“A Discussion on Corporate Venture Capital”

Elaine V. Jones, Ph.D.
Executive Director, Venture Capital- Worldwide Business Development
Pfizer Inc.

Interviewed by:
Paunie Samreth
Reporter
mergermarket

4:40pm – 4:45pm

Argyle Executive Forum Closing Remarks

4:45pm – 5:45pm

Closing Reception

*Please note agenda is subject to change